A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

You may not be if

• 2. No prior systemic treatment for metastatic NSCLC.
• 3. Agreement to provide archival tissue or fresh biopsy (if archival tissue is not available).
• 4. Tumors with PD-L1 expressed in ≥ 50% tumor cells.
• 5. At least 1 measurable lesion as defined per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
• 6. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
• 1. Known mutations in the epidermal growth factor receptor (EGFR) gene, anaplastic lymphoma kinase (ALK) fusion oncogene, BRAF V600E, or ROS1.
• 2. Prior therapy with an anti-programmed cell death protein (anti-PD)-1, anti-PD-ligand (L)-1, anti-PD-ligand-2, anti-T-cell immunoglobulin and ITIM (anti-TIGIT) domain, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways.
• 3. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
• 4. Active autoimmune diseases or history of autoimmune diseases that may relapse.